Dexfenfluramine

Dexfenfluramine

Gene therapy
Clinical data
ATC code	A08AA04 (WHO)
Physiological data
Legal status
Legal status	Schedule IV (US DEA)
Pharmacokinetic data
Protein binding	36%
Elimination half-life	17-20 hours
Identifiers
IUPAC name N-Ethyl-1-[3-(trifluoromethyl)phenyl]-propan-2-amine
CAS Number	3239-44-9
PubChem Template:Abbreviation	3337
DrugBank	APRD00648
Chemical and physical data
Formula	C12H16F3N
Molar mass	231.257 g/mol

WikiDoc Resources for Dexfenfluramine
Articles
Most recent articles on Dexfenfluramine Most cited articles on Dexfenfluramine Review articles on Dexfenfluramine Articles on Dexfenfluramine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Dexfenfluramine Images of Dexfenfluramine Photos of Dexfenfluramine Podcasts & MP3s on Dexfenfluramine Videos on Dexfenfluramine
Evidence Based Medicine
Cochrane Collaboration on Dexfenfluramine Bandolier on Dexfenfluramine TRIP on Dexfenfluramine
Clinical Trials
Ongoing Trials on Dexfenfluramine at Clinical Trials.gov Trial results on Dexfenfluramine Clinical Trials on Dexfenfluramine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Dexfenfluramine NICE Guidance on Dexfenfluramine NHS PRODIGY Guidance FDA on Dexfenfluramine CDC on Dexfenfluramine
Books
Books on Dexfenfluramine
News
Dexfenfluramine in the news Be alerted to news on Dexfenfluramine News trends on Dexfenfluramine
Commentary
Blogs on Dexfenfluramine
Definitions
Definitions of Dexfenfluramine
Patient Resources / Community
Patient resources on Dexfenfluramine Discussion groups on Dexfenfluramine Patient Handouts on Dexfenfluramine Directions to Hospitals Treating Dexfenfluramine Risk calculators and risk factors for Dexfenfluramine
Healthcare Provider Resources
Symptoms of Dexfenfluramine Causes & Risk Factors for Dexfenfluramine Diagnostic studies for Dexfenfluramine Treatment of Dexfenfluramine
Continuing Medical Education (CME)
CME Programs on Dexfenfluramine
International
Dexfenfluramine en Espanol Dexfenfluramine en Francais
Business
Dexfenfluramine in the Marketplace Patents on Dexfenfluramine
Experimental / Informatics
List of terms related to Dexfenfluramine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. It was for some years in the mid-1990s approved by the United States Food and Drug Administration for the purposes of weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn. After it was removed in the US, dexfenfluramine was also pulled out in other global markets. It was later superseded by sibutramine, which is a safer alternative to both dexfenfluramine and fenfluramine.

The drug was manufactured by Interneuron Pharmaceuticals and marketed by Wyeth-Ayerst Laboratories. It is the enantiomer of levofenfluramine.

See also

• Fen-phen

References

• FDA Announces Withdrawal Fenfluramine and Dexfenfluramine (Fen-Phen)